News

Congenica raises funds for genome analysis

Monday 27 February 2017
Country
United Kingdom

Congenica Ltd has raised £8 million in a Series B financing round to support the expanded marketing of its technology for analysing genome-scale DNA data. Known as Sapientia, the platform produces diagnostic reports that can be linked to symptoms patients show for genetic diseases.

InDex Pharma prepares for Phase 2b study

Monday 27 February 2017
Country
Sweden

InDex Pharmaceuticals Holding AB, which is developing treatments for immunological diseases, reported unchanged revenue for 2016 and a widening of its operating deficit as it prepares to take its lead product for ulcerative colitis into a proof-of-concept trial.

Lead Pharma, Sanofi progress partnership

Monday 27 February 2017
Country
Netherlands

Lead Pharma Holding BV has reported progress in its collaboration with Sanofi SA to develop new medicines for autoimmune diseases. A second milestone, the size of which was not disclosed, has been paid to the Dutch company by its Big Pharma partner.

Parathyroid therapy recommended

Saturday 25 February 2017
Country
United Kingdom

The European Medicines Agency is recommending approval of Natpar (parathyroid hormone) to treat patients with chronic hypoparathyroidism who require more than calcium and vitamin D. If approved by the European Commission, Natpar would be the first hormone replacement therapy for this condition.

Galapagos had a good year

Friday 24 February 2017
Country
Belgium

Galapagos NV more than doubled its revenue in 2016 while paring its operating loss to a manageable €11.4 million compared with €89.4 million a year earlier. Moreover, the Belgian company finished the year with cash holdings of €980.9 million, which was greater than the cumulative investments made by all equity investors in the company since its founding in 1999.

Sweden’s HealthCap invests in new radiotherapy company

Friday 24 February 2017
Country
Sweden

Sweden-based venture capital fund HealthCap has provided funds to a new company that is developing alpha-particle emitting radiotherapeutics for cancer. Fusion Pharmaceuticals of Canada has raised $25 million in a Series A financing round.

Ablynx has higher revenue, operating loss

Thursday 23 February 2017
Country
Belgium

Ablynx NV, which has a portfolio of therapeutic proteins derived from the llama, reported a 10% increase in revenue to €85.2 million for 2016, but a wider operating loss of €28.6 million mainly due to higher clinical research expenses.

Robust growth at UCB

Thursday 23 February 2017
Country
Belgium

Belgium-based UCB SA saw its underlying profit increase by 26% to €1.03 billion in 2016 as its core neurology and immunology products achieved higher sales and the growth in operating expenses was kept in check. Further profit growth is expected this year.

Genmab reports 60% higher revenue in 2016

Thursday 23 February 2017
Country
Denmark

Genmab A/S reported a 60% increase in revenue to DKK 1.8 billion (€244.27 million) in 2016, largely due to higher than expected royalties on sales of Darzalex (daratumumab), a treatment for multiple myeloma, as well as milestone payments from its licensee Janssen Biotech Inc.

FDA approves new psoriasis drug

Thursday 23 February 2017
Country
United States

The US Food and Drug Administration has approved the monoclonal antibody brodalumab to treat adults with moderate-to-severe plaque psoriasis, an autoimmune disorder that causes patches of redness and flaking on the skin.